PH12021552135A1 - Methods of treating al amyloidosis - Google Patents
Methods of treating al amyloidosisInfo
- Publication number
- PH12021552135A1 PH12021552135A1 PH1/2021/552135A PH12021552135A PH12021552135A1 PH 12021552135 A1 PH12021552135 A1 PH 12021552135A1 PH 12021552135 A PH12021552135 A PH 12021552135A PH 12021552135 A1 PH12021552135 A1 PH 12021552135A1
- Authority
- PH
- Philippines
- Prior art keywords
- amyloidosis
- methods
- treating
- patients
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—Three-dimensional [3D] image rendering
- G06T15/06—Ray-tracing
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—Three-dimensional [3D] image rendering
- G06T15/50—Lighting effects
- G06T15/506—Illumination models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Computer Graphics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814252P | 2019-03-05 | 2019-03-05 | |
| US201962942722P | 2019-12-02 | 2019-12-02 | |
| PCT/IB2020/000186 WO2020178638A1 (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552135A1 true PH12021552135A1 (en) | 2022-08-31 |
Family
ID=70476256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552135A PH12021552135A1 (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Country Status (17)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55209A (fr) * | 2019-03-05 | 2022-01-12 | Prothena Biosciences Ltd | Procédés de traitement de l'amylose al |
| WO2022056484A1 (en) * | 2020-09-14 | 2022-03-17 | Caelum Biosciences | Method of treating amyloidosis |
| TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
| KR20240133743A (ko) * | 2022-01-11 | 2024-09-04 | 프로테나 바이오사이언시즈 리미티드 | Al 아밀로이드증 치료 방법 |
| TW202506727A (zh) * | 2023-04-10 | 2025-02-16 | 美商麥迪紐有限責任公司 | 優化的cd3抗原結合結構域 |
| TW202547553A (zh) * | 2024-02-06 | 2025-12-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| BR112014009866A2 (pt) * | 2011-10-25 | 2018-09-04 | Onclave Therapeutics Limited | formulações de anticorpos e métodos |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下製剤及びその使用 |
| RS63446B1 (sr) * | 2016-06-30 | 2022-08-31 | Prothena Biosciences Ltd | Kompozicije za lečenje amiloidoze |
| US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| CA3129890A1 (en) | 2019-02-12 | 2020-08-20 | Prothena Biosciences Limited | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
| MA55209A (fr) * | 2019-03-05 | 2022-01-12 | Prothena Biosciences Ltd | Procédés de traitement de l'amylose al |
| TW202332465A (zh) | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
-
2020
- 2020-03-05 MA MA055209A patent/MA55209A/fr unknown
- 2020-03-05 MX MX2021010665A patent/MX2021010665A/es unknown
- 2020-03-05 SG SG11202109645Q patent/SG11202109645QA/en unknown
- 2020-03-05 PH PH1/2021/552135A patent/PH12021552135A1/en unknown
- 2020-03-05 AU AU2020231081A patent/AU2020231081A1/en active Pending
- 2020-03-05 US US16/810,319 patent/US11692024B2/en active Active
- 2020-03-05 WO PCT/IB2020/000186 patent/WO2020178638A1/en not_active Ceased
- 2020-03-05 BR BR112021017550A patent/BR112021017550A2/pt unknown
- 2020-03-05 JP JP2021552586A patent/JP7619953B2/ja active Active
- 2020-03-05 KR KR1020217031814A patent/KR20220019656A/ko not_active Ceased
- 2020-03-05 CN CN202080033593.5A patent/CN113811332A/zh active Pending
- 2020-03-05 EP EP20722638.2A patent/EP3934689B1/en active Active
- 2020-03-05 EP EP25163966.2A patent/EP4582446A3/en not_active Withdrawn
- 2020-03-05 CA CA3132780A patent/CA3132780A1/en active Pending
-
2021
- 2021-06-16 FR FR2106376A patent/FR3111560B1/fr active Active
- 2021-09-01 IL IL286040A patent/IL286040A/en unknown
- 2021-09-03 CL CL2021002318A patent/CL2021002318A1/es unknown
- 2021-09-05 JO JOP/2021/0245A patent/JOP20210245A1/ar unknown
-
2023
- 2023-05-08 US US18/313,792 patent/US12240894B2/en active Active
-
2025
- 2025-01-09 JP JP2025003299A patent/JP2025063135A/ja active Pending
- 2025-03-03 US US19/068,630 patent/US20250188159A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250188159A1 (en) | 2025-06-12 |
| KR20220019656A (ko) | 2022-02-17 |
| BR112021017550A2 (pt) | 2021-11-09 |
| EP3934689A1 (en) | 2022-01-12 |
| CN113811332A (zh) | 2021-12-17 |
| SG11202109645QA (en) | 2021-10-28 |
| JOP20210245A1 (ar) | 2023-01-30 |
| IL286040A (en) | 2021-10-31 |
| FR3111560B1 (fr) | 2024-03-22 |
| AU2020231081A1 (en) | 2021-09-30 |
| US12240894B2 (en) | 2025-03-04 |
| JP2025063135A (ja) | 2025-04-15 |
| MX2021010665A (es) | 2021-12-10 |
| WO2020178638A1 (en) | 2020-09-10 |
| EP3934689B1 (en) | 2025-04-23 |
| FR3111560A1 (fr) | 2021-12-24 |
| JP7619953B2 (ja) | 2025-01-22 |
| EP4582446A2 (en) | 2025-07-09 |
| CL2021002318A1 (es) | 2022-05-06 |
| US11692024B2 (en) | 2023-07-04 |
| MA55209A (fr) | 2022-01-12 |
| EP4582446A3 (en) | 2025-08-13 |
| CA3132780A1 (en) | 2020-09-10 |
| US20230331831A1 (en) | 2023-10-19 |
| JP2022522889A (ja) | 2022-04-20 |
| US20200308260A1 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2022009366A (es) | Compuestos y usos de estos. | |
| MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
| MY205760A (en) | Humanized antibodies against c-kit | |
| MY208231A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| PH12021551451A1 (en) | Combination hbv therapy | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MY190411A (en) | Improved uricase sequences and methods of treatment | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| MX2020011738A (es) | Uso de calcifediol en pacientes de cirugia bariatrica. | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al | |
| MX2023008835A (es) | Métodos de tratamiento de la amiloidosis al. | |
| WO2019179823A8 (en) | Lactobacillus fermentum for treating fructose-related diseases | |
| MX2021012130A (es) | Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad. | |
| MA53909B1 (fr) | Compositions et méthodes de stimulation ovarienne contrôlée | |
| MX2022013883A (es) | Compuestos de metiltioninio para uso en el tratamiento de covid-19. |